Investigating Cancer Treatment Pathways and Contextual Factors Affecting Guideline Adoption in Nigeria - Top-Institutions - MDSpire

Investigating Cancer Treatment Pathways and Contextual Factors Affecting Guideline Adoption in Nigeria

  • By

  • Sylvia Shirima

  • Adewumi Alabi

  • Tonia Onyeka

  • Khadidiatou Ndiaye

  • Oluwasuen Adebayo Bamodu

  • Ramin Asgary

  • April 15, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Cancer Survivorship
    • Implementation Science

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Cancer Survivorship
    • Global Health

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Oncology
    • Implementation Science
    • Global Oncology

  • #4

    University of Ibadan - University College Hospital
    University of Ibadan - University College Hospital

    Ibadan, Oyo

    Key Differentiators

    • Oncology
    • Cancer Care Delivery
    • Global Health

  • #5

    African Cancer Institute (University of Cape Town)
    African Cancer Institute (University of Cape Town)

    Cape Town, Western Cape

    Key Differentiators

    • Oncology
    • Cancer Survivorship
    • Implementation Science

Original Source(s)

Investigating Cancer Treatment Pathways and Contextual Factors Affecting Guideline Adoption in Nigeria

  • by Sylvia Shirima, Adewumi Alabi, Tonia Onyeka, Khadidiatou Ndiaye, Oluwasuen Adebayo Bamodu, Ramin Asgary

  • April 15, 2026

Related Content

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer